Ascendis Pharma A (ASND) Receivables Refunds (2016 - 2025)
Ascendis Pharma A (ASND) has disclosed Receivables Refunds for 9 consecutive years, with $2.1 million as the latest value for Q4 2025.
- Quarterly Receivables Refunds rose 9.3% to $2.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.1 million through Dec 2025, up 9.3% year-over-year, with the annual reading at $2.1 million for FY2025, 9.3% up from the prior year.
- Receivables Refunds hit $2.1 million in Q4 2025 for Ascendis Pharma A, up from $1.9 million in the prior quarter.
- In the past five years, Receivables Refunds ranged from a high of $2.1 million in Q4 2025 to a low of $862903.8 in Q4 2023.
- Historically, Receivables Refunds has averaged $1.4 million across 5 years, with a median of $1.0 million in 2021.
- Biggest five-year swings in Receivables Refunds: fell 11.81% in 2022 and later surged 119.81% in 2024.
- Year by year, Receivables Refunds stood at $1.0 million in 2021, then decreased by 11.81% to $900878.4 in 2022, then decreased by 4.22% to $862903.8 in 2023, then soared by 119.81% to $1.9 million in 2024, then grew by 9.3% to $2.1 million in 2025.
- Business Quant data shows Receivables Refunds for ASND at $2.1 million in Q4 2025, $1.9 million in Q4 2024, and $862903.8 in Q4 2023.